These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 15317405)

  • 41. Prevention of venous thromboembolism in the orthopedic surgery patient.
    Deitelzweig SB; McKean SC; Amin AN; Brotman DJ; Jaffer AK; Spyropoulos AC
    Cleve Clin J Med; 2008 Apr; 75 Suppl 3():S27-36. PubMed ID: 18494224
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fondaparinux, the first selective factor Xa inhibitor.
    Turpie AG; Eriksson BI; Lassen MR; Bauer KA
    Curr Opin Hematol; 2003 Sep; 10(5):327-32. PubMed ID: 12913785
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Venous thromboembolism prevention with LMWHs in medical and orthopedic surgery patients.
    Deitelzweig SB; Vanscoy GJ; Niccolai CS; Rihn TL
    Ann Pharmacother; 2003 Mar; 37(3):402-11. PubMed ID: 12639173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Setting a standard for venous thromboembolism prophylaxis.
    Turpie AG
    Am J Health Syst Pharm; 2001 Nov; 58 Suppl 2():S18-23. PubMed ID: 11715835
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fondaparinux: a new synthetic and selective inhibitor of Factor Xa.
    Bauer KA
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):89-104. PubMed ID: 15171960
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery.
    Comp PC
    Pharmacotherapy; 2003 Jun; 23(6):772-87. PubMed ID: 12820819
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Emerging options for thromboprophylaxis after orthopedic surgery: a review of clinical data.
    Lobo BL
    Pharmacotherapy; 2004 Jul; 24(7 Pt 2):66S-72S. PubMed ID: 15317401
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current perspectives on the treatment of venous thromboembolism: need for effective, safe and convenient new antithrombotic drugs.
    O'Shaughnessy DF
    Int J Clin Pract; 2004 Mar; 58(3):277-84. PubMed ID: 15117096
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis.
    Bauer KA
    Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):4-10. PubMed ID: 12463577
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin.
    Turpie AG; Norris TM
    Thromb Haemost; 2004 Jul; 92(1):3-12. PubMed ID: 15213839
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current concepts for the prevention of venous thromboembolism.
    Bramlage P; Pittrow D; Kirch W
    Eur J Clin Invest; 2005 Mar; 35 Suppl 1():4-11. PubMed ID: 15701142
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Traditional versus modern anticoagulant strategies: summary of the literature.
    Nutescu E; Racine E
    Am J Health Syst Pharm; 2002 Oct; 59(20 Suppl 6):S7-14. PubMed ID: 12400244
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy.
    Turpie AG
    Expert Opin Pharmacother; 2004 Jun; 5(6):1373-84. PubMed ID: 15163281
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of venous thromboembolism in the elderly.
    Spyropoulos AC; Merli G
    Drugs Aging; 2006; 23(8):651-71. PubMed ID: 16964988
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Fondaparinux sodium.
    Reverter JC
    Drugs Today (Barc); 2002 Mar; 38(3):185-94. PubMed ID: 12532174
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Duration of venous thromboembolism prophylaxis after surgery.
    Kearon C
    Chest; 2003 Dec; 124(6 Suppl):386S-392S. PubMed ID: 14668422
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prevention of venous thromboembolism following orthopaedic surgery: clinical potential of direct thrombin inhibitors.
    Eriksson BI; Dahl OE
    Drugs; 2004; 64(6):577-95. PubMed ID: 15018589
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery.
    Raskob GE; Hirsh J
    Chest; 2003 Dec; 124(6 Suppl):379S-385S. PubMed ID: 14668421
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Economics of unfractionated heparin: beyond acquisition cost.
    Dobesh PP;
    Pharmacotherapy; 2004 Aug; 24(8 Pt 2):161S-164S. PubMed ID: 15334863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.